Every 10-Q that RETINALGENIX TECHNOLOGIES (RTGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RTGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RTGN filings page.
RetinalGenix Technologies Inc. reported no revenue for the three and six months ended June 30, 2026 and continues to operate as a pre-commercial ophthalmic R&D company. Net loss was $307,397 for the quarter and $897,886 for the first half, narrower than the prior-year periods, driven mainly by lower general and administrative and stock-based compensation expenses, partially offset by higher research and development spending on the RetinalCam project.
At June 30, 2026, cash was $27,232 against total liabilities of $2,672,914 and an accumulated deficit of $18,756,503, leaving a stockholders’ deficit of $2,640,699. The company discloses substantial doubt about its ability to continue as a going concern and estimates it needs about $7,000,000 in additional capital to advance product development, genetic testing, and its AI database. Operations remain heavily supported by related party Sanovas, to which $996,007 was owed at June 30, 2026; this balance was subsequently exchanged for 442,670 common shares.
The company sold 88,889 shares at $2.25 per share during the period, maintains significant potential dilution through 780,000 stock options, 1,950,000 warrants, and a 28,014,540-share pre-funded warrant, and reports a continuing material weakness in internal control over financial reporting due to lack of segregation of duties.
RetinalGenix Technologies Inc. reported another quarterly loss and severe liquidity pressure for the quarter ended March 31, 2026. The company generated no revenue and recorded a net loss of $590,489, similar to the prior year period, driven by $262,149 of general and administrative costs, $117,064 of research and development, and $210,016 of stock-based compensation.
Cash fell to just $180 at March 31, 2026 against total liabilities of $2,563,889 and an accumulated deficit of $18,449,106, leaving a significant stockholders’ deficit. Management discloses “substantial doubt” about the company’s ability to continue as a going concern and estimates it needs about $7,000,000 in additional capital to advance its retinal imaging devices, DNA/GPS genetic testing platform, and related AI database toward commercialization. Operations remain heavily supported by related-party Sanovas, which is owed about $830,632. The filing also notes a continuing material weakness in internal control over financial reporting due to lack of segregation of duties.
RetinalGenix Technologies (RTGN) filed its Q3 2025 10‑Q, reporting no revenue and a smaller quarterly net loss of $568,791 versus $644,291 a year ago. Operating expenses fell to $567,833 on lower R&D and stock‑based compensation, while interest expense was negligible.
Liquidity is strained: cash was $92 at September 30, 2025 against total liabilities of $2,179,731 and a stockholders’ deficit of $(2,172,730). The company discloses “substantial doubt” about its ability to continue as a going concern and is in discussions to raise capital and explore a potential up‑listing. Related‑party payables include $539,052 due to Sanovas as of quarter‑end.
For the nine months, net loss improved to $1,805,468 from $3,453,800 on sharply lower stock‑based compensation. RTGN sold 82,666 shares for $186,000 year‑to‑date and subsequently sold 12,000 shares for $27,000. A material weakness in internal control over financial reporting (lack of segregation of duties) remains. Common shares outstanding were 18,604,961 at November 14, 2025.